Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

HIV/AIDS

Souleymane Mboup, Rosemary Musonda, Fred Mhalu, Max Essex
Dean T Jamison, Richard G Feachem, Malegapuru W Makgoba, Eduard R Bos, Florence K Baingana, Karen J Hofman, Khama O Rogo
, editors.
In: Disease and Mortality in Sub-Saharan Africa. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 17.
Free Books & Documents
Review

HIV/AIDS

Souleymane Mboup et al.
Free Books & Documents

Excerpt

The epidemic of HIV/AIDS is unprecedented, having expanded from a new disease to the leading cause of death in Sub-Saharan Africa in just over two decades. Despite some clear examples of success, such as Senegal for prevention, and Uganda for control, major new measures are needed to avoid further devastation. The epidemic in Africa is uneven, with the greatest burden in southern Africa, where populations are already experiencing major reductions in life expectancy and a reversal of progress in the management of national economies.

About two-thirds of the world's HIV infections are in Sub-Saharan Africa in just 10 percent of the world's population. Because HIV/AIDS in the Americas and Europe is uncommon in women and rare in children, Africa holds more than 90 percent of the world's burden on such issues as child mortality and the care of orphans.

At present, prevention strategies are largely limited to education for changes in sexual practices and the use of condoms. Vaccines and microbicides represent an extremely important area of research, but useful products are not likely to be available in less than 5 to 10 years. ARV drug treatment programs have begun in Africa but are as yet very modest in impact. Operational research to maximize the benefits of ARV use will be important to address treatment efficacy and drug resistance, the impact on health manpower resources, and cost-effectiveness. The full devastation of AIDS in Africa has yet to be fully appreciated. Still, an increase in awareness and willingness to act should give cause for optimism.

PubMed Disclaimer

References

    1. Barin F., Mboup S., Denis F., Kanki P., Allan J. S., Lee T. H., Essex M. Serological Evidence for Virus Related to Simian T-Lymphotropic Retrovirus III in Residents of West Africa. Lancet. 1985;2:1387–89. - PubMed
    1. Barre-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C. et al. Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) Science. 1983;220:868–71. - PubMed
    1. Bouvet, E., A. Laporte, and A. Tarantola. 2002. "Postexposure Prophylaxis for Occupational Exposure and Sexual Assault." In AIDS in Africa, ed. M. Essex, S. Mboup, P. Kanki, R. Marlink, and S. Tlou, 571–83. New York: Kluwer Academic/Plenum Publishers.
    1. CIA (Central Intelligence Agency). 2006. The World Factbook.http://www. cia.gov/cia/publications/factbook/(accessed January 13, 2006).
    1. Clumeck N., Mascart-Lemone F., de Maubeuge J., Brenez D., Marcelis L. Acquired Immune Deficiency Syndrome in Black Africans. Lancet. 1983;1:642. - PubMed

LinkOut - more resources